Evidence map›Paper›PMID 42830607›Full record

ArticleChemical biology & drug design2026

Triazole-Linked Pyrimidine Nucleoside Dimers: Design, Synthesis, and Applications in Medicinal and Nucleic Acid Chemistry. Part IV.

Dagmara Baraniak, Dariusz Wawrzyniak, Daniel Baranowski

Abstract read
In one paragraph

Article in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dagmara BaraniakInstitute of Bioorganic Chemistry, Polish Academy of Sciences, Poznań, Poland.ORCID https://orcid.org/0000-0002-0970-8297
Dariusz WawrzyniakInstitute of Bioorganic Chemistry, Polish Academy of Sciences, Poznań, Poland.ORCID https://orcid.org/0000-0002-6128-5383
Daniel BaranowskiInstitute of Bioorganic Chemistry, Polish Academy of Sciences, Poznań, Poland.ORCID https://orcid.org/0000-0002-4346-4804

Funding

National Science Centre Poland 2017/01/X/ST5/00381National Science Centre Poland 2019/35/D/NZ7/03637
6 · The paper itself

Abstract

A new class of pyrimidine nucleoside dimers featuring an ultrashort 1,4-disubstituted 1,2,3-triazole linker was designed and synthesized to explore the biological potential of structurally robust nucleoside analogues as anticancer agents. The target compounds were efficiently obtained via Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) from appropriately functionalized 3'-azido- and 4'-ethynyl-5'-deoxy-5'-nor nucleoside precursors and fully characterized by multinuclear 1D/2D NMR spectroscopy and ESI-MS. Their antiproliferative activity was evaluated against a panel of human cancer cell lines comprising cervical (HeLa), breast (T47D), ovarian (SK-OV-3), and glioblastoma (U-138 MG and U-251 MG) cells, with MRC-5 human fibroblasts serving as the control. Several dimers displayed pronounced and cell line-selective antiproliferative activity while exhibiting limited toxicity toward normal cells. Dimers 4, 9, 11, and 17 demonstrated the highest activity against HeLa cells, whereas Dimers 7 and 15 were the most potent against U-251 MG glioblastoma cells, with activities comparable to or exceeding that of 5-fluoro-2'-deoxyuridine (5FdU). Mechanistic studies performed on the most active glioblastoma-directed dimers revealed a concentration-dependent reduction in clonogenic survival and cell migration, accompanied by increased cell death and pronounced S-phase cell cycle arrest, closely resembling the effect of the reference compound 5FdU. In contrast, only a modest and transient increase in intracellular reactive oxygen species (ROS) was detected, indicating that oxidative stress is unlikely to represent the primary mechanism responsible for their antiproliferative activity. Preliminary structure-activity relationship analysis demonstrated that both the nature of the nucleobase and the rigid triazole-linked dimeric architecture substantially influence biological activity and selectivity. Moreover, the synthesized dimers exhibited excellent chemical stability in cell culture medium and human serum, highlighting their exceptional resistance to degradation. Taken together, these findings identify triazole-linked pyrimidine nucleoside dimers as highly stable bioactive scaffolds that inhibit glioblastoma cell proliferation through disruption of DNA synthesis rather than oxidative stress and represent promising candidates for further development as anticancer agents or durable nucleic acid-targeting molecular tools.

Indexed as

Antineoplastic AgentsDrug DesignPyrimidine NucleosidesTriazolesCell Line, TumorCell ProliferationDimerizationHeLa CellsHumansReactive Oxygen SpeciesAntineoplastic AgentsPyrimidine NucleosidesReactive Oxygen SpeciesTriazoles1,2,3‐triazol4′‐ethynyl‐5′‐deoxy‐5′‐nor‐nucleosideAddUAFddUanticancer activityAZTclick chemistryCuAACnucleoside dimersSAR

Identifiers

PMID42830607
PMCPMC13635774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.